Carisma Therapeutics CEO to Speak at Stifel 2024 Cell Therapy Forum

Carisma Therapeutics

PHILADELPHIA, PACarisma Therapeutics Inc. (Nasdaq: CARM) announced that Steven Kelly, its President and Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Cell Therapy Forum. The event is scheduled for Tuesday, July 9th at 9:10 am ET.

An audio webcast of Kelly’s session will be available on Carisma’s Investor Relations webpage. The recording will be archived for a limited time after the event.

The Stifel 2024 Cell Therapy Forum is a notable event in the field of cell therapy. It will be held virtually and feature presentations from numerous companies and institutions. Among the participants is Immix Biopharma, Inc., a clinical-stage biopharmaceutical company. Immix Biopharma will present on their lead cell therapy, NXC-201, which targets BCMA using chimeric antigen receptor T (CAR-T) cell technology and is currently in Phase 1b/2 trials.

Kelly’s appearance at the forum will highlight Carisma Therapeutics’ ongoing efforts to advance cell therapy technologies. His insights are expected to shed light on the company’s strategies and the broader implications of their work in treating diseases.

The forum offers a platform for industry leaders to discuss innovations and developments in cell therapy, providing investors and stakeholders with valuable information on emerging treatments and clinical progress.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.

READ:  Qlik Launches Qlik Talend Cloud to Boost AI Data Trust and Accessibility